Different Iron-Deposition Patterns of Multiple System Atrophy with Predominant Parkinsonism and Idiopathetic Parkinson Diseases Demonstrated by Phase-Corrected Susceptibility-Weighted Imaging

References

1. 1.↵
   1. Stankiewicz J,
   2. Panter SS,
   3. Neema M,
   4. et al

   . Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007; 4: 371– 86

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Thomas M,
   2. Jankovic J

   . Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol 2004; 17: 437– 42

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Zhu WZ,
   2. Zhong WD,
   3. Wang W,
   4. et al

   . Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. Radiology 2009; 253: 497– 504

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Haacke EM,
   2. Makki M,
   3. Ge Y,
   4. et al

   . Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009; 29: 537– 44

   CrossRefPubMed
5. 5.↵
   1. Berg D,
   2. Hochstrasser H

   . Iron metabolism in Parkinsonian syndromes. Mov Disord 2006; 21: 1299– 310

   CrossRefPubMedWeb of Science
6. 6.↵
   1. van Royen E,
   2. Verhoeff NF,
   3. Speelman JD,
   4. et al

   . Multiple system atrophy and progressive supranuclear palsy: diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol 1993; 50: 513– 16

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Schulz JB,
   2. Klockgether T,
   3. Petersen D,
   4. et al

   . Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994; 57: 1047– 56

   Abstract/FREE Full Text
8. 8.↵
   1. Poewe W,
   2. Wenning G

   . The differential diagnosis of Parkinson's disease. Eur J Neurol 2002; 9 (suppl 3): 23– 30

   PubMedWeb of Science
9. 9.↵
   1. Wenning GK,
   2. Colosimo C

   . Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy. Rev Neurol (Paris) 2010; 166: 829– 33. Epub 2010 Sep 1

   CrossRefPubMed
10. 10.↵
    1. Ordidge RJ,
    2. Gorell JM,
    3. Deniau JC,
    4. et al

    . Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 1994; 32: 335– 41

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Gelman N,
    2. Gorell JM,
    3. Barker PB,
    4. et al

    . MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 1999; 210: 759– 67

    PubMedWeb of Science
12. 12.↵
    1. Bartzokis G,
    2. Tishler TA,
    3. Lu PH,
    4. et al

    . Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 2007; 28: 414– 23

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Pfefferbaum A,
    2. Adalsteinsson E,
    3. Rohlfing T,
    4. et al

    . MRI estimates of brain iron concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI) methods. Neuroimage 2009; 47: 493– 500

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Jensen JH,
    2. Szulc K,
    3. Hu C,
    4. et al

    . Magnetic field correlation as a measure of iron-generated magnetic field inhomogeneities in the brain. Magn Reson Med 2009; 61: 481– 85

    CrossRefPubMed
15. 15.↵
    1. Bartzokis G,
    2. Cummings JL,
    3. Markham CH,
    4. et al

    . MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 1999; 17: 213– 22

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Bartzokis G,
    2. Cummings J,
    3. Perlman S,
    4. et al

    . Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999; 56: 569– 74

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Bartzokis G,
    2. Tishler TA

    . MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease. Cell Mol Biol (Noisy-le-grand) 2000; 46: 821– 33

    PubMedWeb of Science
18. 18.↵
    1. Bartzokis G,
    2. Tishler TA,
    3. Shin IS,
    4. et al

    . Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci 2004; 1012: 224– 36

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Bishop GM,
    2. Robinson SR,
    3. Liu Q,
    4. et al

    . Iron: a pathological mediator of Alzheimer disease? Dev Neurosci 2002; 24: 184– 87

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Martin WR,
    2. Roberts TE,
    3. Ye FQ,
    4. et al

    . Increased basal ganglia iron in striatonigral degeneration: in vivo estimation with magnetic resonance. Can J Neurol Sci 1998; 25: 44– 47

    PubMedWeb of Science
21. 21.↵
    1. Sipe JC,
    2. Lee P,
    3. Beutler E

    . Brain iron metabolism and neurodegenerative disorders. Dev Neurosci 2002; 24: 188– 96

    CrossRefPubMed
22. 22.↵
    1. Schrag A,
    2. Good CD,
    3. Miszkiel K,
    4. et al

    . Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697– 702

    Abstract/FREE Full Text
23. 23.↵
    1. Yekhlef F,
    2. Ballan G,
    3. Macia F,
    4. et al

    . Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003; 110: 151– 69

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Reichenbach JR,
    2. Venkatesan R,
    3. Yablonskiy DA,
    4. et al

    . Theory and application of static field inhomogeneity effects in gradient-echo imaging. J Magn Reson Imaging 1997; 7: 266– 79

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Haacke EM,
    2. Cheng NY,
    3. House MJ,
    4. et al

    . Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005; 23: 1– 25

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Haacke EM,
    2. Xu Y,
    3. Cheng YC,
    4. et al

    . Susceptibility weighted imaging (SWI). Magn Reson Med 2004; 52: 612– 18

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Ogg RJ,
    2. Langston JW,
    3. Haacke EM,
    4. et al

    . The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. Magn Reson Imaging 1999; 17: 1141– 48

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Hughes AJ,
    2. Daniel SE,
    3. Kilford L,
    4. et al

    . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181– 84

    Abstract/FREE Full Text
29. 29.↵
    1. Gilman S,
    2. Low PA,
    3. Quinn N,
    4. et al

    . Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163: 94– 98

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Haacke EM,
    2. Ayaz M,
    3. Khan A,
    4. et al

    . Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain. J Magn Reson Imaging 2007; 26: 256– 64

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Haacke EM,
    2. Miao Y,
    3. Liu M,
    4. et al

    . Correlation of putative iron content as represented by changes in R2* and phase with age in deep gray matter of healthy adults. J Magn Reson Imaging 2010; 32: 561– 76

    CrossRefPubMed
32. 32.↵
    1. Hallgren B,
    2. Sourander P

    . The effect of age on the non-haemin iron in the human brain. J Neurochem 1958; 3: 41– 51

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Bartzokis G,
    2. Mintz J,
    3. Sultzer D,
    4. et al

    . In vivo MR evaluation of age-related increases in brain iron. AJNR Am J Neuroradiol 1994; 15: 1129– 38

    Abstract/FREE Full Text
34. 34.↵
    1. Kurisaki H,
    2. Yomono H,
    3. Murayama S,
    4. et al

    . Multiple system atrophy with a-/hypo-ceruloplasminemia: distribution of iron in brains of 2 autopsy cases [in Japanese]. Rinsho Shinkeigaku 2002; 42: 293– 98

    PubMed
35. 35.↵
    1. Spokes EG,
    2. Bannister R,
    3. Oppenheimer DR

    . Multiple system atrophy with autonomic failure: clinical, histological and neurochemical observations on four cases. J Neurol Sci 1979; 43: 59– 82

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Fearnley JM,
    2. Lees AJ

    . Striatonigral degeneration: a clinicopathological study. Brain 1990; 113 (pt 6): 1823– 42

    Abstract/FREE Full Text
37. 37.↵
    1. Vymazal J,
    2. Righini A,
    3. Brooks RA,
    4. et al

    . T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999; 211: 489– 95

    PubMedWeb of Science
38. 38.↵
    1. Kraft E,
    2. Trenkwalder C,
    3. Auer DP

    . T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease. Neurology 2002; 59: 1265– 67

    Abstract/FREE Full Text
39. 39.↵
    1. von Lewinski F,
    2. Werner C,
    3. Jorn T,
    4. et al

    . T2*-weighted MRI in diagnosis of multiple system atrophy: a practical approach for clinicians. J Neurol 2007; 254: 1184– 88

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Lantos PL,
    2. Papp MI

    . Cellular pathology of multiple system atrophy: a review. J Neurol Neurosurg Psychiatry 1994; 57: 129– 33

    FREE Full Text
41. 41.↵
    1. Kraft E,
    2. Schwarz J,
    3. Trenkwalder C,
    4. et al

    . The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 1999; 56: 225– 28

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Brass SD,
    2. Chen NK,
    3. Mulkern RV,
    4. et al

    . Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 2006; 17: 31– 40

    CrossRefPubMed
43. 43.↵
    1. Atasoy HT,
    2. Nuyan O,
    3. Tunc T,
    4. et al

    . T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol India 2004; 52: 332– 37

    PubMed
44. 44.↵
    1. Kosta P,
    2. Argyropoulou MI,
    3. Markoula S,
    4. et al

    . MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 2006; 253: 26– 32

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Gorell JM,
    2. Ordidge RJ,
    3. Brown GG,
    4. et al

    . Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995; 45: 1138– 43

    Abstract/FREE Full Text
46. 46.↵
    1. Graham JM,
    2. Paley MN,
    3. Grunewald RA,
    4. et al

    . Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000; 123 (pt 12): 2423– 31

    Abstract/FREE Full Text
47. 47.↵
    1. Michaeli S,
    2. Oz G,
    3. Sorce DJ,
    4. et al

    . Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 2007; 22: 334– 40

    CrossRefPubMed
48. 48.↵
    1. Feng F,
    2. You H,
    3. Wang H,
    4. et al

    . Phase-weighted imaging in differentiating multiple system atrophy from idiopathic Parkinson disease [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2009; 31: 129– 33

    PubMed
49. 49.↵
    1. Gupta D,
    2. Saini J,
    3. Kesavadas C,
    4. et al

    . Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 2010; 52: 1087– 94

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Wang YH,
    2. Dai YM,
    3. Xu HB

    . High iron percentage in human brain-idiopathic Parkinsons, Parkinsonism and healthy cases. DOI: 10.1594/ecr2010/C-2511. 2010